BioSpace News Archive

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development. Mr. McClung’s appointment is the latest in the evolution of Sangamo’s leadership implemented over the last three years as t

Debiotech will be collaborating with vaccine companies, foundations and public organizations, using its unique DebioJect™ Microneedle, to improve the effectiveness of COVID-19 vaccines by reducing the necessary dose to achieve a sufficient immune response.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that its products and product lines are gaining significant traction and acceptance in Asia

Coram, the company’s infusion care business, will help transition eligible IV-therapy patients out of the hospital and other care settings by providing in-home nursing

Vizient applauds the decision announced by the Food and Drug Administration to allow compounding pharmacies to begin producing a range of pharmaceuticals used for coronavirus patients, including many medications necessary for those on ventilators.

HALIX B.V. has joined a consortium of partners under the guidance of the University of Oxford, to provide GMP manufacturing services supporting the large scale production of a COVID-19 vaccine (ChAdOx1 nCoV-19), being developed by the University’s Jenner Institute. This GMP manufacturing scale-up is taking place alongside early phase clinical trials.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with high unmet medical need, is pleased to announce the appointment of Dr. Vanessa Almendro Navarro, of Eisai US, as an independent director

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today that, since the emergence of the COVID-19 pandemic, the company has been implementing and executing contingency plans necessary to ensure the health and safety of its employees, partners and clinical trial participants.

Company Providing Dialysis Machines to Hospitals Due to Increase in Patients with Acute Kidney Injury

New Study Published by the Centers for Disease Control and Prevention Finds Novel Coronavirus May Travel On Footwear; Hands-Free Footwear Brand Rushes 1,000 Pairs of Shoes to Healthcare Workers on the Front Lines Who Need Them Most [17-April-2020] VINEYARD, Utah , April 17, 2020 /PRNewswire/ -- Data from a new study published by the Centers for Disease Control and